United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $552.56, for a total value of $4,586,248.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $24,960,240.32. This represents a 15.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

United Therapeutics Trading Up 1.6%

Shares of UTHR stock opened at $555.91 on Friday. The company has a market cap of $23.60 billion, a price-to-earnings ratio of 20.52, a price-to-earnings-growth ratio of 1.80 and a beta of 0.58. The stock has a 50 day simple moving average of $558.71 and a 200-day simple moving average of $527.64. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the business earned $6.63 earnings per share. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current fiscal year.

Institutional Trading of United Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Geneos Wealth Management Inc. lifted its position in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 70 shares during the last quarter. Jump Financial LLC acquired a new position in shares of United Therapeutics in the second quarter valued at approximately $277,000. Cerity Partners LLC lifted its stake in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock valued at $3,691,000 after buying an additional 5,600 shares during the period. Finally, Bank of Nova Scotia lifted its stake in shares of United Therapeutics by 6.9% during the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after buying an additional 105 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the topic of several research analyst reports. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Royal Bank Of Canada cut their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. HC Wainwright raised their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a report on Thursday, May 7th. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.